| Patent application number | Description | Published |
|---|
| 20100003259 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 01-07-2010 |
| 20100040624 | Human Tumor Necrosis Factor TR21 and Methods Based Thereon - The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity. | 02-18-2010 |
| 20100111953 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 05-06-2010 |
| 20110117093 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 05-19-2011 |
| 20110293610 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR PROTEIN - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 12-01-2011 |
| 20120058119 | HUMAN TUMOR NECROSIS FACTOR TR21 AND METHODS BASED THEREON - The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity. | 03-08-2012 |
| Patent application number | Description | Published |
|---|
| 20100291081 | RAGE FUSION PROTEINS - The present invention provides novel therapeutics and methods of treatment for diseases associated with activation of the advanced glycation endproducts receptor (RAGE). | 11-18-2010 |
| 20110182887 | HUMANIZED ANTI-CD22 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE - The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients. | 07-28-2011 |
| Patent application number | Description | Published |
|---|
| 20080233174 | HIGH DOSE FILM COMPOSITIONS AND METHODS OF PREPARATION - This invention relates to films incorporating high amounts of pharmaceutical agents and methods for the preparation of the same. Moreover, the invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. | 09-25-2008 |
| 20090104270 | Film delivery system for tetrahydrolipstatin - The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including tetrahydrolipstatin, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided. | 04-23-2009 |
| 20110033541 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form. | 02-10-2011 |
| 20110033542 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS - The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent. | 02-10-2011 |
| Patent application number | Description | Published |
|---|
| 20090291757 | SYSTEMS, METHODS, AND APPARATUS FOR CONTROLLING A GAMING MACHINE DISPLAY - A gaming machine is provided including a display unit configured to generate video images, an input unit, an ambient light sensor, and a controller coupled to the display unit, input unit, and ambient light sensor. The controller is configured to receive physical characteristics of a player via the input unit, determine an ambient light level of an environment of the gaming machine based on a signal generated by the ambient light sensor, determine a desired brightness level for video images based on the determined ambient light level, determine a desired contrast level for the video images based on the received physical characteristics or the determined ambient light level, generate display settings for the video images based on the determined brightness level and the determined contrast level, and display the graphics to the player via the display unit using the generated display settings. | 11-26-2009 |
| 20100120484 | GAMING SYSTEM, GAMING DEVICE AND METHOD PROVIDING A GROUP OF TIMED GAMES - The gaming system, gaming device and gaming method provides a plurality of sequential player events in which the player must take an action in a designated period of time and where the player has less time to take the action in each subsequent event. | 05-13-2010 |
| 20100120506 | GAMING DEVICE AND METHOD OF PROVIDING AN ADJUSTED PAYTABLE FOR A NUMBER OF FUTURE PLAYS OF A GAME - One embodiment of the present disclosure provides a game operable upon a wager by a player which initially employs an initial or default paytable. The gaming device enables a player to place wagers on plays of the game. The gaming device displays the game outcomes and provides the player with any awards based on the game outcomes in accordance with the default paytable. Upon an occurrence of a triggering event, a bonus mode is triggered. In one embodiment, when the bonus mode is triggered, the gaming device offers to replace the default paytable with a different one of the paytables for a limited number of future plays of the game, if the player agrees to make an additional wager on each of those future plays of the game. If the player chooses to accept the offer, the gaming device determines outcomes and provides any awards for the limited number of future plays in accordance with the new paytable, as long as the player continues placing the additional wager for each of those plays. If the player chooses not to accept the offer to replace the default paytable with a new paytable, the gaming device displays the number of future plays of the game without requiring the additional wager and provides any awards for those plays in accordance with the default paytable. | 05-13-2010 |
| Patent application number | Description | Published |
|---|
| 20080314797 | Integrated hydroprocessing with high productivity catalysts - Integrated hydroprocessing methods using high activity, low density catalysts are provided. The high activity catalysts allow for lower temperature operation, which reduces catalyst degradation, while the low density of the catalysts means a corresponding reduction in the amount of metal needed to fill a reactor volume. The methods allow for flexible processing of feedstocks with a variety of wax contents. | 12-25-2008 |
| 20090005627 | Integrated hydroprocessing with high productivity catalysts - Integrated hydroprocessing methods using high activity, low density catalysts are provided. The high activity catalysts allow for blocked operation when processing lube range feedstocks of widely varying characteristics, such as wax content, without having to substantially change the configuration or operating conditions of the process train. Instead, the different feedstocks can be accommodated by varying the reaction temperature in the process train. | 01-01-2009 |
| 20090166251 | All catalytic medicinal white oil production - All catalytic process for producing white oils is provided. More particularly, medicinal grade white oils are produced from a process including hydrotreating and/or hydrocracking, catalytic dewaxing followed by hydrofinishing to produce a medicinal white oil. | 07-02-2009 |
| 20100176027 | Sour service hydroprocessing for diesel fuel production - An integrated process for producing diesel fuel from feedstocks, including diesel fuel production under sour conditions, is provided. The ability to process feedstocks under higher sulfur and/or nitrogen conditions allows for reduced cost processing and increases the flexibility in selecting a suitable feedstock. In addition to the benefits in sour service, the process also returns to clean service activity levels more quickly. | 07-15-2010 |
| 20110056869 | FUEL PRODUCTION FROM FEEDSTOCK CONTAINING LIPIDIC MATERIAL - This invention relates to the production of dewaxed and/or hydroisomerized fuel composition that includes a step of hydrotreating a feedstock containing the lipidic material. The fuel compositions are high quality fuel compositions in which the fuel can be ultimately tailored for a variety of end uses such as jet fuel or diesel fuel. | 03-10-2011 |
| 20110132803 | TWO STAGE HYDROPROCESSING WITH DIVIDED WALL COLUMN FRACTIONATOR - A divided wall column allows for fractionation of multiple streams while maintaining separate product qualities. Effluents from multiple stages of a reaction system can be processed in a single divided wall column. The divided wall column can produce multiple cuts from each separated area, as well as at least one output from a common area. | 06-09-2011 |
| 20110163009 | HYDROPROCESSING OF HIGH NITROGEN FEED USING BULK CATALYST - Methods are provided for hydrotreating high nitrogen feeds with improved results for nitrogen removal, aromatic saturation, and/or sulfur removal. The method includes hydrotreating the feed with a supported hydrotreating catalyst followed by a bulk metal catalyst, the hydrotreated effluent of which can be suitable for use as a feed to an FCC reactor. | 07-07-2011 |
| 20110219669 | Hydroprocessing of diesel range biomolecules - Non-hydrotreated biocomponent feeds can be mixed with mineral feeds and processed under catalytic isomerization/dewaxing conditions. The catalytic isomerization/dewaxing conditions can be selected to advantageously also substantially deoxygenate the mixed feed. Diesel fuel products with improved cold flow properties can be produced. | 09-15-2011 |
| 20110219671 | DEWAXING OF RENEWABLE DIESEL FUEL - Feeds containing a hydrotreated biocomponent portion, and optionally a mineral portion, can be processed under catalytic conditions for isomerization and/or dewaxing. The sulfur content of the feed for dewaxing can be selected based on the hydrogenation metal used for the catalyst. Diesel fuel products with improved cold flow properties can be produced. | 09-15-2011 |
| 20110219672 | HYDROPROCESSING OF BIODIESEL FUELS AND BLENDS - A method for producing diesel fuel from biocomponent feeds includes hydrotreating the feed followed by catalytic dewaxing with a ZSM-48 containing catalyst. The hydrotreated feed may be cascaded directly to the dewaxing step, or the hydrotreated feed can undergo intermediate separation. The diesel fuel resulting from processing of the biocomponent feed exhibits superior cetane values. | 09-15-2011 |
| 20110259793 | Low pressure production of low cloud point diesel - A diesel fuel product with beneficial cold flow properties can be produced. A suitable feedstock for forming a diesel boiling range product can be hydrotreated to have a sulfur content of at least about 100 wppm and then dewaxed. This two stage process can allow for production of an arctic or winter diesel without use of high pressures. Optionally, a divided wall column fractionator can be used to allow a single separation stage to handle the effluent from both the hydroprocessing and the dewaxing stages. | 10-27-2011 |
| 20120080357 | HYDROCRACKING PROCESS SELECTIVE FOR IMPROVED DISTILLATE AND IMPROVED LUBE YIELD AND PROPERTIES - This invention relates to a process involving hydrocracking of a feedstream in which a converted fraction can exhibit relatively high distillate product yields and maintained or improved distillate fuel properties, while an unconverted fraction can exhibit improved properties particularly useful in the lubricant area. | 04-05-2012 |
